Limits...
Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus

LCZ696 to enalapril hazard ratio (line) and 95% confidence intervals (shaded area) for clinical outcomes [cardiovascular death or heart failure hospitalization (A), cardiovascular death (B), heart failure hospitalization (C), and all-cause mortality (D)] according to age. A hazard ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of <1.0 favours LCZ696.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4595742&req=5

EHV330F2: LCZ696 to enalapril hazard ratio (line) and 95% confidence intervals (shaded area) for clinical outcomes [cardiovascular death or heart failure hospitalization (A), cardiovascular death (B), heart failure hospitalization (C), and all-cause mortality (D)] according to age. A hazard ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of <1.0 favours LCZ696.

Mentions: The hazard ratio (HR), i.e. the effect of LCZ696 compared with enalapril on the primary outcome, was consistent across the spectrum of age (Table 2 and Figure 2A), with a P-value for interaction of 0.94.Figure 2


Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF.

Jhund PS, Fu M, Bayram E, Chen CH, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJ, Packer M, PARADIGM-HF Investigators and Committe - Eur. Heart J. (2015)

LCZ696 to enalapril hazard ratio (line) and 95% confidence intervals (shaded area) for clinical outcomes [cardiovascular death or heart failure hospitalization (A), cardiovascular death (B), heart failure hospitalization (C), and all-cause mortality (D)] according to age. A hazard ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of <1.0 favours LCZ696.
© Copyright Policy - creative-commons
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4595742&req=5

EHV330F2: LCZ696 to enalapril hazard ratio (line) and 95% confidence intervals (shaded area) for clinical outcomes [cardiovascular death or heart failure hospitalization (A), cardiovascular death (B), heart failure hospitalization (C), and all-cause mortality (D)] according to age. A hazard ratio of 1.0 is indicated by the solid horizontal line. A hazard ratio of <1.0 favours LCZ696.
Mentions: The hazard ratio (HR), i.e. the effect of LCZ696 compared with enalapril on the primary outcome, was consistent across the spectrum of age (Table 2 and Figure 2A), with a P-value for interaction of 0.94.Figure 2

Bottom Line: The findings for HFH were similar for CV and all-cause mortality and the age category by treatment interactions were not significant.The pre-specified safety outcomes of hypotension, renal impairment and hyperkalaemia increased in both treatment groups with age, although the differences between treatment (more hypotension but less renal impairment and hyperkalaemia with LCZ696) were consistent across age categories.LCZ696 was more beneficial than enalapril across the spectrum of age in PARADIGM-HF with a favourable benefit-risk profile in all age groups.

View Article: PubMed Central - PubMed

Affiliation: BHF Cardiovascular Research Centre, Institute of Cardiovascular and Medical Sciences, University of Glasgow, 126 University Place, Glasgow G12 8TA, UK.

No MeSH data available.


Related in: MedlinePlus